

Discover Genetic Heterogeneity in Cancer

The Chromium Single Cell CNV Solution

Breast cancer is a complex disease with a high degree of inter- and intra-tumor heterogeneity (1). Clinically, breast cancers are commonly categorized into subtypes based on the expression pattern of the predictive and prognostic biomarkers ER, PR, and HER2. Bulk copy number variation (CNV) patterns have also been used to further sub-categorize tumors but traditional bulk measurements can only recover the average genetic profile and may miss clinically-relevant variants in minor sub-clones (2-5). With the Chromium Single Cell CNV Solution, we demonstrate that single cell resolution is necessary to unmask genetic heterogeneity.

Single Cell CNVs Reveal Tumor Heterogeneity




Figure 1

We profiled CNVs at single cell resolution from snap-frozen breast tumor tissue obtained from Bioserve. Using the Chromium Single Cell CNV Solution, we obtained integer-scaled CNV profiles across the genome for each cell (145 cells). We visualized the results as a heatmap. This analysis revealed two distinct populations: a homogeneous diploid population likely representing normal cells (57 cells) and a heterogeneous population displaying CNV amplifications likely corresponding to tumor cells (67 cells). Diploid cells showed a high degree of coverage uniformity with a near-linear relationship between genome fraction and number of reads.

Amplifications of Regions Implicated in Cancer




Figure 2

To highlight chromosomal regions with genetic variation, we plotted the observed ploidy in 1-Mb intervals across the genome, varying the point size to reflect fraction of tumor single cells with that ploidy. Chromosome 6 is shown as example. In this tumor, chromosome 6 shows a high degree of variability. The region with the highest gains in ploidy overlaps with a METABRIC driver somatic copy number aberration region (6) and includes the AIM1 gene. The fact that the majority of the tumor cells show a ploidy >15 at the chromosome 6 hyper-amplified regions suggests the possibility of a double minute, though this would need further confirmation with a cytogenetic experiment.

Spatial Segregation of Clones

Figure 3A




Figure 3B





Figure 3C



We analyzed a second breast tumor that we sectioned into 2 sectors (S1 and S2). Using the Chromium Single Cell CNV Solution on each section (S1 – 602 cells, S2 – 671 cells), we identified clusters of cells based on similarity of their CNV profiles (Figure 3A). The proportion of cells in each cluster was markedly different between sectors (Figure 3A, 3B). The heterogeneity of the S1 and S2 tumor regions is revealed only at single cell resolution, since the pseudo-bulk CNV profiles for the two sectors show an overall ploidy of 2 across the genome (Figure 3C).

Conclusions

Using the Chromium Single Cell CNV Solution on breast tumor samples, we demonstrated that tumor heterogeneity can be dissected based on CNV detection empowered by robust genome representation and coverage uniformity. We also showed that the tumor heterogeneity is distributed spatially and is revealed only at single cell resolution. The characterization of tumors at single cell resolution is key to understanding the true nature and distribution of tumor heterogeneity, which will be key to understanding tumor evolution and identifying driver regions and new therapeutic targets.

Resources

Datasets	go.10xgenomics.com/scCNV/datasets
Videos	go.10xgenomics.com/scCNV/videos
Application Notes	go.10xgenomics.com/scCNV/app-notes
Technical Support	go.10xgenomics.com/scCNV/support
Publications	go.10xgenomics.com/scCNV/pubs
Cell Ranger DNA Analysis Pipelines	go.10xgenomics.com/scCNV/cell-ranger-dna
Loupe scDNA Browser:	go.10xgenomics.com/scCNV/loupe-scDNA

Legal Notices

For 10x Genomics legal notices visit:
10xgenomics.com/legal-notices

Citations

1. K. K. Shiu *et al.*, DNA amplifications in breast cancer: genotypic-phenotypic correlations. *Future Oncol.* 6, 967-984 (2010).
2. N.R. Bertos, M. Park, Breast cancer - one term, many entities? *J. Clin. Invest.* 121, 3789-3796 (2011).
3. J.S. Beckmann *et al.*, Copy number variants and genetic traits: closer to the resolution of phenotypic to genotypic variability. *J. Nat. Rev. Genet.* 8, 639-646 (2007).
4. K. Polyak, Heterogeneity in breast cancer. *J. Clin. Invest.* 121, 3786-3788 (2011).
5. N. McGranahan, C. Swanton, Clonal heterogeneity and tumor evolution: Past, present, and the future. *Cell* 168, 613-628 (2017).
6. C. Curtis *et al.*, The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* 486, 346-352 (2012).

Support

support@10xgenomics.com
 10x Genomics
 6230 Stoneridge Mall Road
 Pleasanton, CA 94588-3260

Spatial Segregation of Clones

Figure 3A






Figure 3C



We analyzed a second breast tumor that we sectioned into 2 sectors (S1 and S2). Using the Chromium Single Cell CNV Solution on each section (S1 – 602 cells, S2 – 671 cells), we identified clusters of cells based on similarity of their CNV profiles (Figure 3A). The proportion of cells in each cluster was markedly different between sectors (Figure 3A, 3B). The heterogeneity of the S1 and S2 tumor regions is revealed only at single cell resolution, since the pseudo-bulk CNV profiles for the two sectors show an overall ploidy of 2 across the genome (Figure 3C).

Figure 3B



Conclusions

Using the Chromium Single Cell CNV Solution on breast tumor samples, we demonstrated that tumor heterogeneity can be dissected based on CNV detection empowered by robust genome representation and coverage uniformity. We also showed that the tumor heterogeneity is distributed spatially and is revealed only at single cell resolution. The characterization of tumors at single cell resolution is key to understanding the true nature and distribution of tumor heterogeneity, which will be key to understanding tumor evolution and identifying driver regions and new therapeutic targets.

Resources

Datasets	go.10xgenomics.com/scCNV/datasets
Videos	go.10xgenomics.com/scCNV/videos
Application Notes	go.10xgenomics.com/scCNV/app-notes
Technical Support	go.10xgenomics.com/scCNV/support
Publications	go.10xgenomics.com/scCNV/pubs
Cell Ranger DNA Analysis Pipelines	go.10xgenomics.com/scCNV/cell-ranger-dna
Loupe scDNA Browser:	go.10xgenomics.com/scCNV/loupe-scDNA

Citations

1. K. K. Shiu *et al.*, DNA amplifications in breast cancer: genotypic-phenotypic correlations. *Future Oncol.* 6, 967-984 (2010).
2. N.R. Bertos, M. Park, Breast cancer - one term, many entities? *J. Clin. Invest.* 121, 3789-3796 (2011).
3. J.S. Beckmann *et al.*, Copy number variants and genetic traits: closer to the resolution of phenotypic to genotypic variability. *J. Nat. Rev. Genet.* 8, 639-646 (2007).
4. K. Polyak, Heterogeneity in breast cancer. *J. Clin. Invest.* 121, 3786-3788 (2011).
5. N. McGranahan, C. Swanton, Clonal heterogeneity and tumor evolution: Past, present, and the future. *Cell* 168, 613-628 (2017).
6. C. Curtis *et al.*, The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* 486, 346-352 (2012).

Support

support@10xgenomics.com
 10x Genomics
 6230 Stoneridge Mall Road
 Pleasanton, CA 94588-3260

© 2019 10X Genomics, Inc. (10x Genomics). All rights reserved. Duplication and/or reproduction of all or any portion of this document without the express written consent of 10x Genomics, is strictly forbidden. Nothing contained herein shall constitute any warranty, express or implied, as to the performance of any products described herein. Any and all warranties applicable to any products are set forth in the applicable terms and conditions of sale accompanying the purchase of such product. 10x Genomics provides no warranty and hereby disclaims any and all warranties as to the use of any third-party products or protocols described herein. The use of products described herein is subject to certain restrictions as set forth in the applicable terms and conditions of sale accompanying the purchase of such product. A non-exhaustive list of 10x Genomics' marks, many of which are registered in the United States and other countries can be viewed at: www.10xgenomics.com/trademarks. 10x Genomics may refer to the products or services offered by other companies by their brand name or company name solely for clarity, and does not claim any rights in those third-party marks or names. 10x Genomics products may be covered by one or more of the patents as indicated at: www.10xgenomics.com/patents. All products and services described herein are intended FOR RESEARCH USE ONLY and NOT FOR USE IN DIAGNOSTIC PROCEDURES. The use of 10x Genomics products in practicing the methods set forth herein has not been validated by 10x Genomics, and such non-validated use is NOT COVERED BY 10X GENOMICS STANDARD WARRANTY, AND 10X GENOMICS HEREBY DISCLAIMS ANY AND ALL WARRANTIES FOR SUCH USE. Nothing in this document should be construed as altering, waiving or amending in any manner 10x Genomics terms and conditions of sale for the Chromium Controller or the Chromium Single Cell Controller, consumables or software, including without limitation such terms and conditions relating to certain use restrictions, limited license, warranty and limitation of liability, and nothing in this document shall be deemed to be Documentation, as that term is set forth in such terms and conditions of sale. Nothing in this document shall be construed as any representation by 10x Genomics that it currently or will at any time in the future offer or in any way support any application set forth herein.